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Abstract 
 
Background/Aim. Helicobacter (H.) pylori is a widespread 
bacterium and its involvement in pathogenesis of gastric 
diseases is well-known. However, H. pylori role in etiology of 
other histologically similar conditions, especially recurrent 
aphthous stomatitis (RAS) is still controversial. Research re-
garding H. pylori and its association with RAS, as well as the 
treatment options were always conducted on patients with 
diagnosed gastric problems. The aim of this study was to 
determine whether H. pylori is present in the oral cavity of 
patients suffering from RAS but without any symptoms or 
medical history of gastric disease. Methods. A total of 15 
patients with RAS participated in the study. None of the 
participants suffered from any gastrointestinal disorders. 
Two dental plaque samples from each participant were col-
lected. The first was analyzed using rapid urease test and the 
second one was put in transport medium and sent for culti-
vation. The sensitivity of H. pylori to antibiotics was estab-
lished using disk diffusion method of sensitivity testing for 
every patient individually and adequate therapy was pre-
scribed. Results. Before the treatment the mean annual re-
currence rate of RAS was 8.1 ± 2.1, with the average num-
ber of lesions being 3.9 ± 1.9. During the 12-month obser-
vation period after the eradication therapy, none of the pa-
tients reported recurrence of aphthous lesions. The treat-
ment was successful in all cases. Conclusion. This study 
shows that RAS can be effectively treated by successful era-
dication of oral H. pylori, and that RAS could be possibly 
considered as an early warning sign of potential gastric in-
fection by H. pilory. 
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Apstrakt 
 
Uvod/Cilj. Helicobacter (H.) pylori je široko rasprostanjena 
bakterija i njen uticaj na nastanak gastričkih oboljenja vrlo 
dobro je dokumentovan. Međutim, uloga H. pylori u 
patogenezi histološki sličnih oboljenja, posebno rekurentnog 
aftoznog stomatitisa (RAS), nije dovoljno istražena. 
Dosadašnje studije, u kojima je ispitivana veza između H. 
pylori i RAS, kao i moguće terapijske opcije, bile su usmerene 
ka bolesnicima sa prethodno dijagnostikovanim gastričkim 
smetnjama. Cilj ovog istraživanja bio je da se utvrdi da li je H. 
pylori prisutan u usnoj duplji i kod bolesnika bez simptoma i 
istorije gastričkih oboljenja koji pate od RAS. Metode. U 
studiji je učestvovalo 15 bolesnika koji pate od RAS. Bolesnici 
nisu imali smetnje vezane za gornji deo digestivnog trakta. Po 
dva uzorka dentalnog plaka prikupljena su od svakog 
bolesnika. Jedan plak je ispitivan uz pomoć brzog ureaza 
testa, dok je drugi stavljen u transportni medijum i poslat na 
kultivaciju. Osetljivost H. pylori na antibiotike određivana je uz 
pomoć antibiograma za svakog bolesnika posebno i, u skladu 
sa rezultatima, prepisivana je odgovarajuća terapija. 
Rezultati. Pre lečenja prosečan broj epizoda RAS tokom 
godine iznosio je 8,1 ± 2,1, sa prosečno 3,9 ± 1,9 aftoznih 
lezija. Tokom 12-mesečnog perioda nakon eradikacione 
terapije, ni kod jednog bolesnika nije došlo do ponovne 
pojave afti. Terapija je bila uspešna kod svih bolesnika. 
Zaključak. Rezultati ovog istraživanja pokazuju da se RAS 
može uspešno lečiti eradikacijom H. pylori i da se sama pojava 
RAS može posmatrati kao rano upozorenje na moguću 
gastričku infekciju. 
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Introduction 
Helicobacter (H.) pylori is a widespread microaerophi-
lic, Gram-negative, spiral bacterium associated with gastro-
intestinal disorders. Its involvement in pathogenesis of gas-
tritis, gastric ulcers and malignancies is well-known 1, 
however, its role in etiology of other histologically similar 
conditions, especially recurrent aphthous stomatitis (RAS), is 
still controversial. Several studies tried to determine if H. 
pylori is present in aphthous lesions but the results were not 
very convincing 2–4. Despite that, other authors 5, 6 suggested 
that H. pylori could be one of the important causative factors 
in RAS pathogenesis. Another conflicting issue is whether H. 
pylori is a resident or transient member of oral microflora, 
and can oral cavity act as a reservoir of these bacteria 7, 8.  
Eradication treatment (triple therapy) of H. pylori is the 
therapy of choice for patients suffering from gastroduodenal 
diseases. It consists of two antibiotics and proton pump inhi-
bitor, and this therapy course is supported by a wide consen-
sus 9, 10. Studies showed that eradication can also have positi-
ve effects on patients suffering from RAS, regarding recur-
rence rate, the number of lesions and severity of 
symptoms 5, 11. However, this treatment may fail mostly due 
to H. pylori resistance to one of the antibiotics used 12.  
Research regarding H. pylori and its association with 
RAS, as well as the treatment options were always conducted 
on patients with diagnosed gastric problems. In this study we 
tried to determine whether H. pylori is present in the oral 
cavity of patients suffering from RAS but without any 
symptoms or medical history implying gastric disease and 
can eradication, based on antibiotic sensitivity testing results, 
eliminate or reduce RAS symptoms. 
Methods 
A total of 15 patients (7 men and 8 women, aged 30 to 
50) with RAS participated in the study. None of the partici-
pants suffered from any gastrointestinal disorders (dyspepsia, 
heartburn or peptic ulcer) and had not consumed any antibio-
tics at least 1 month prior to the sample collecting. Samples 
were collected during the active phase of RAS; diagnosis 
was made clinically at the time of examination at the Depar-
tment of Restorative Dentistry and Endodontics, Faculty of 
Dental Medicine, Belgrade, Serbia.  
The patients were given detailed questionnaire regar-
ding history of aphthae appearance, their number and locali-
zation, as well as any pain and unpleasantness associated 
with the condition. Plaque index by Silness-Löe was measu-
red for each patient. 
Per two dental plaque subgingival samples from each 
participant were collected using a dental probe. The first was 
analyzed using rapid urease test (Bramio H. pylori test, The 
Institute for Immunology and Virology, Torlak, Belgrade, 
Serbia). The urease test was kept at 37°C and the result was 
read after 1, 2, and between 3 and 24 h; the values +++, ++, 
+ were assigned, respectively, if the results were positive; the 
test was regarded positive if color had changed from yellow 
to red. The second sample was put into transport medium 
and sent for cultivation (Institute of Microbiology and 
Immunology, Faculty of Medicine, University of Belgrade, 
Belgrade, Serbia). Columbia agar (bioMerieux, France) enri-
ched with 7% horse blood (The Institute for Immunology 
and Virology, Torlak, Belgrade, Serbia), 5% yeast extracts 
an essential amino acids was used as culture medium for cul-
tivating H. pylori. Cultivation was done in microaerophilic 
conditions (Generbag, bioMerieux, France) at 37°C. Identifi-
cation of H. pylori was done by typical colony (grey, circular 
and translucent) and microscopic characteristics (Gram-
negative curved, thin bacterium), and biochemical tests.  
The sensitivity of H. pylori to antibiotics was establis-
hed using the disk diffusion method for isolates from each 
patient individually, and adequate therapy was prescribed. 
Antibiotics taken into consideration were amoxicillin, 
doxycycline, erythromycin, ciprofloxacin, clarithromycin 
and metronidazole. Treatment consisted of two antibiotics 
that H. pylori was most sensitive on, and lasted for ten days. 
One month after the eradication treatment patients were 
recalled and control samples were obtained. Procedures for 
identifying H. pylori were repeated. Plaque index by Silness-
Löe was also measured.  
A control period was 12 months. During this time pati-
ents were monitored for potential recurrence of aphthous le-
sions.  
Data were analyzed using the statistical package (SPSS 
version 17.01, SPSS Inc, Chicago, IL, USA). The sample si-
ze was established in 15 patients, to obtain the power higher 
than 80% (α = 0.05), on the basis of the results from the 
study of Whitley and Ball 13. Paired t-test was used to com-
pare plaque index and χ2-test for cultivation and rapid urease 
test results before and after eradication treatment. A p-value 
of < 0.05 was used to assign statistical significance for all 
tests. All descriptive statistics are presented as mean ± sta-
ndard deviation (SD). 
Results 
All of the 15 patients chosen for this study completed 
the protocol. The average age of patients was 38 ± 6 years. 
Aphthous lesions were located on lower lip (20.0%), buccal 
mucosa (53.3%) and hard palate (26.7%). 
The average plaque index by Silness-Löe at the first 
examination was 1.67 ± 0.20. One month after the treatment, 
there was no statistical difference in plaque index values 
(1.64 ± 0.21). 
Rapid urease test was positive for all the patients, and 
for 13 of them the color of the test changed during the first 
hour (8 of them in the first 20 min). Two samples were labe-
led positive within the second hour. All of the colonies 
showed growth and were identified as H. pylori. After the 
treatment, rapid urease tests were negative for 14 patients 
and one test showed discrete color change after 24 h (p < 
0.05), and there were no visible colonies in culture mediums 
(p < 0.05) (Table 1).  
Before the treatment the mean annual recurrence rate 
was 8.1 ± 2.1, with the average number of lesions being 3.9 
± 1.9. During the 12-month follow-up after the eradication 
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Table 1  
Results of the patients testing for Helicobacter pylori before and after the eradication treatment 
Positive finding, n (%) Variable Negative finding, n (%)  After 1 h After 2 h After 3–24 h 
Rapid urease test     
before treatment 0 13 (86.7) 2 (13.3) 0 
after treatment 14 (93.3) 0 0 1 (6.67) 
Culture     
before treatment 0   15 (100) 
after treatment 15 (100)   0 
 
 
therapy, none of the patients reported recurrence of aphthous 
lesions. The treatment was successful in all 15 patients. 
Discussion 
This study showed the 100% treatment success, but the-
se results should be taken with caution due to the small sam-
ple number. Other studies reported significant accomplish-
ments but with a fairly lower success rate 5, 14. It can be 
explained by the fact that we managed to overcome bacterial 
resistance and improve therapy result following the results of 
sensitivity testing 10. Plaque index values did not have any 
influence on the effect of eradication treatment. 
Recent studies used modern polymerase chain reaction 
(PCR) methods for identifying H. pylori presence based on 
its DNA 15, 16 but design of this study demanded bacterial 
cultivation because only viable, active bacterial colonies co-
uld be tested on sensitivity to antibiotics. Sampling was done 
from gingival sulcus to obtain dental plaque because of 
complex biofilm structure that can provide better environ-
ment for colonization of H. pylori 17.  
Rapid urease test was used as an additional way to 
indirectly confirm the presence of H. pylori based on its ure-
ase activity. Although there are a number of oral bacteria that 
can give positive test results, time in which color of test 
changed (within the first 2 h for 14 of the samples analyzed) 
suggested the presence of a microorganism with very high 
urease activity. A positive result in one sample after 24 h co-
uld be contributed to oral bacteria. In subgingival biofilm 
formations there are bacteria that can give positive rapid ure-
ase test result, but with lower urease activity that would take 
longer time for positive result; this indicates the presence of 
H. pylori in study participants 18. 
This preliminary study shows that H. pylori can be fo-
und in oral environment for longer periods of time. Recur-
rence of aphthous lesions and their absence after H. pylori 
eradication prove a connection between this bacteria and 
etiology of RAS, so we can assume that it was present during 
the whole course of the disorder, and that oral cavity can act 
as a reservoir. These findings are in correlation with other 
studies 16, 19–21; however, there are also authors 4, 22 with diffe-
rent opinions. 
RAS is the most common disorder of the oral mucosa 
with the prevalence up to 50% in general population 23. The 
cause is not entirely clear, but many factors have been consi-
dered in its etiology 24. H. pylori, as stated previously, is one 
of the possible factors, but the exact mechanism of this mic-
roorganism contributing to RAS pathogenesis is still uncle-
ar 5, 6. The results of this study show that successful eradica-
tion of oral H. pylori could treat RAS very effectively, altho-
ugh larger study group should be analyzed.  
Knowing that H. pylori is among the most infectious 
human pathogens, infecting an estimated 50% of the global 
population 10, any means of preventing its propagation sho-
uld be taken into consideration. 
Conclusion 
The fact that the patients with RAS included in this study 
were not suffering from gastric disorders can possibly be used as 
a measure of prevention and that RAS can be taken as an early 
warning sign of potential gastric infection by H. pylori.  
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